Clinic
Dearborn Pain Center PLLC
Dearborn Pain Center PLLC was paid $3.28M by Medicaid between Feb 2019 and Dec 2024, across 58 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 29% of everything it billed.
33Billing provider infoDEARBORN PAIN CENTER PLLC
HAZEL PARK, MI 48030
HAZEL PARK, MI 48030
33aNPI1174995203assigned 10/28/2015
33bProvider typeUrgent Care Clinic/Center
28Total paid$3.28M
24GClaims95,190
24DCodes billed58
24AFirst – last monthFeb 2019 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Michigan
Rank by total paid#23 of 239
Median peer was paid$346K
This provider vs. median9.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,096 | $66K | |
| 2020 | 10,975 | $332K | |
| 2021 | 25,211 | $893K | |
| 2022 | 25,706 | $887K | |
| 2023 | 19,096 | $654K | |
| 2024incomplete | 12,106 | $446K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 29% | 17,208 | 14,821 | $960K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 9,848 | 9,014 | $724K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 16% | 7,833 | 7,804 | $513K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 9.9% | 3,623 | 3,609 | $326K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 5.7% | 5,744 | 5,386 | $187K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.2% | 6,549 | 6,244 | $137K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.9% | 5,732 | 4,879 | $61K |
| 99000 | 1.6% | 5,467 | 4,916 | $51K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.3% | 435 | 354 | $42K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 5,527 | 4,357 | $34K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 822 | 748 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,577 | 1,530 | $24K |
46 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,017 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,151 | $23K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 572 | $15K |
| 80305 | <1% | 2,119 | $15K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 265 | $14K |
| 87631 | <1% | 151 | $14K | |
| 81025 | <1% | 1,966 | $11K | |
| 81002 | <1% | 4,858 | $11K | |
| 74019 | <1% | 582 | $10K | |
| 87428 | <1% | 206 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,689 | $6K |
| 99205 | Prolong outpt/office vis | <1% | 49 | $6K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 946 | $4K |
| 87634 | <1% | 95 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 642 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,666 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 226 | $2K |
| 72100 | <1% | 111 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 20 | $2K |
| 73130 | <1% | 97 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 58 | $2K |
| 93000 | <1% | 153 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 615 | $835.51 |
| 73630 | <1% | 27 | $448.80 | |
| 80053 | Comprehensive metabolic panel | <1% | 53 | $279.68 |
| 99406 | <1% | 67 | $255.60 | |
| 69210 | <1% | 12 | $249.57 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 414 | $199.39 |
| 73560 | <1% | 12 | $183.60 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 107 | $171.92 |
| 86580 | <1% | 32 | $165.78 | |
| 99441 | <1% | 30 | $158.40 | |
| 82948 | <1% | 98 | $134.35 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 35 | $113.49 |
| 99001 | <1% | 523 | $90.16 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 485 | $31.89 |
| 99072 | <1% | 393 | $21.75 | |
| 99051 | <1% | 546 | $7.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 114 | $5.34 |
| 3008F | 0% | 195 | $0.00 | |
| 3079F | 0% | 13 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 13 | $0.00 |
| 1000F | 0% | 45 | $0.00 | |
| 3074F | 0% | 174 | $0.00 | |
| 3075F | 0% | 14 | $0.00 | |
| 3078F | 0% | 169 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAYED, MOATAZ (MANAGER)